Phase 2
N=2
Orlistat for the Treatment of Type I Hyperlipoproteinemia
Hyperlipoproteinemia Type I · Hypertriglyceridemia
Bottom Line
View on ClinicalTrials.gov: NCT02767531 ↗Enrolled (actual)
2
Serious AEs
0.0%
Results posted
Feb 2019
Primary outcome: Primary: Fasting Serum Triglycerides — 705; 1827; 1511; 1007 mg/dL
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Orlistat (Drug)
- Age
- Pediatric, Adult · 8+ yrs
- Sex
- All
- Sponsor
- University of Texas Southwestern Medical Center
- Primary completion
- May 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Fasting Serum Triglycerides |
705; 1827; 1511; 1007; 758; 3121 | — |
Summary
Patients with Type I Hyperlipoproteinemia (T1HLP) have a rare form of hypertriglyceridemia marked by significant chylomicronemia and recurrent episodes of acute pancreatitis. T1HLP is caused by a deficiency of lipoprotein lipase or one of its cofactors. Many patients are a challenge to treat, as the only effective therapy available is an extremely low fat diet. This diet is exceedingly difficult to follow, and despite adherence, many patients still have chylomicronemia and develop acute pancreatitis.
Specific Aim: To determine the efficacy of a gastric and pancreatic lipase inhibitor, Orlistat, in reducing serum triglyceride levels in patients with T1HLP.
Eligibility Criteria
Inclusion Criteria
- Type I hyperlipoproteinemia
- Fasting serum triglyceride levels of greater than 1000 mg/dL
- Age > 8 years
Exclusion Criteria
- Secondary hypertriglyceridemias due to diabetes, renal disease, hypothyroidism, alcoholism and drug therapy such as estrogens and estrogen analogues, steroids, HIVprotease inhibitors, retinoic acid derivatives and interferons
- Pregnant or lactating women
- Significant liver disease (elevated transaminases > 2 times upper limit of normal) Alcohol abuse (> 7 drinks or 84 g per week for women and > 14 drinks or 168 g per week for men)
- Severe anemia (hematocrit < 24%)
- Drug use (cocaine, marijuana, LSD, etc.)
- Major surgery in the past three months
- Congestive heart failure
- Serum creatinine greater than 2.5 mg/dL
- Cancer within the past five years
- Gastrointestinal surgery in the past
- Current therapy with anti-coagulants, digoxin, and anti-arrhythmics
- Current therapy with cyclosporine
- Chronic malabsorption syndromes
- Cholestasis
- Acute illnesses such as acute pancreatitis in the last 8 weeks
Data sourced from ClinicalTrials.gov (NCT02767531). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.